Ultragenyx Pharmaceutical (RARE) Gross Profit Growth (1y) (2019 - 2026)

Ultragenyx Pharmaceutical (RARE) Gross Profit Growth (1y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 41.37%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.76%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 16.94%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 68.41%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Ultragenyx Pharmaceutical 2.71 Bn 2.30 Bn 106.00 Mn -3.64%

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.64%
Dec 31, 2025 20.65%
Sep 30, 2025 11.37%
Jun 30, 2025 14.11%
Mar 31, 2025 20.48%
Dec 31, 2024 27.91%
Sep 30, 2024 36.07%
Jun 30, 2024 27.80%
Mar 31, 2024 3.47%
Dec 31, 2023 17.62%
Sep 30, 2023 6.08%
Jun 30, 2023 21.37%
Mar 31, 2023 19.51%
Dec 31, 2022 22.72%
Sep 30, 2022 5.94%
Jun 30, 2022 -3.30%
Mar 31, 2022 -21.62%
Dec 31, 2021 -7.18%
Sep 30, 2021 -2.09%
Jun 30, 2021 39.95%